Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins

(E-pub Abstract Ahead of Print)

Author(s): Qun Zhou*.

Journal Name: Current Drug Targets

Volume 19 , 2018


BACKGROUND: Glycan-binding proteins are widely distributed in human and play an essential role in biological processes. Their involvements in inflammatory and immune responses make it increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets. OBJECTIVE: The current review aims to provide information on recent advancements in clinical developments of antibodies against glycan-binding proteins as potential targets. RESULTS AND CONCLUSION: There are several therapeutic antibodies being developed targeting glycan-binding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.

Keywords: Glycan-binding proteins, Lectins, antibodies, Clinical Development, inflammation, autoimmune diseases, hematological malignancies

Rights & PermissionsPrintExport

Article Details

Year: 2018
(E-pub Abstract Ahead of Print)
DOI: 10.2174/1389450119666180308144313
Price: $95